Get started

Biotech

SNY Fib Levels On The Radar & WhySNY and TBIO buttoned up the news this morning sending a bunch of other biotech stocks running higher. Now that this is out of the way, levels could be important for longs looking for "what's next" and the 236 Fib level seems to be that area to watch. It was an area that the volatile SNY stock settled above for weeks and now is an area it hasn't been able to break above for the last several weeks. Heading into the month after this acquisition, it's gonna be interesting to see if mRNA stocks start to catch a bit more. " A mega buyout from Sanofi (NASDAQ: SNY) has investors looking at biotech stocks today. If you remember our article, “Top Biotech Penny Stocks On Robinhood To Watch This Week,” we discussed Sanofi and its strengthening relationship with a former penny stock, Translate Bio Inc. (NASDAQ: TBIO)...Sanofi had previously pledged to invest 400 million euros annually in a vaccines R&D facility to advance mRNA vaccines with Translate to benefit. Tuesday, Sanofi formally announced a $3.2 billion buyout of its vaccine collaboration partner. This was at $38 a share in cash, roughly 30% higher than the close on August 2nd. " Quote Source & Read More: Hot Biotech Stocks To Watch After Sanofi’s Acquisition Of Translate Bio
NASDAQ:SNY
by PennyStocks101
Can GALT Vault Back Above The 200?Looks like GALT is back hanging out around the 786 level again. This is where it was trading around before the last big spike. But there's also another level to keep track of which is the 200DMA. Now that GALT is below this level, the 200 might be another possible area of resistance. Given the post-market action on Friday (7/30), GALT managed to break above the 200 ($2.82) briefly before sliding back down to that same level by the close of the aftermarket session. Aside from technicals, there are also some fundamental things to note about GALT and you can Read More On GALT stock: 8 ‘Must Watch’ Penny Stocks For Your July 2021 List
NASDAQ:GALT
by PennyStocks101
DOUBLED $ATOS Target 5.69 for 46.27% DOUBLED $ATOS Target 5.69 for 46.27% (Actually I a little bit more than doubled here, but not by too much) Next add level at 2.09 Or Double Position again at 1.48 @Dau30 Here is my new average after doubling this morning… and I have a small order open at 2.80 but I’m watching for 1.48. A WILD day, for sure... ----- — On the far right of the chart is my Average (Grey) Current Target (Green), and Next Level to add (Red) Percentage to target is from my average. ONLY ADD at support levels & FIB levels… labeled I start every position with .5 - 1% of my account and build from there as needed and as possible. I am not your financial advisor. Watch my setups first before you jump in… My trade set ups work very well and they are for my personal reference and if you decide to trade them you do so at your own risk. I will gladly answer questions to the best of my knowledge but ultimately the risk is on you. I will update targets as needed. GL and happy trading.
NASDAQ:ATOSLong
by SPYder_QQQueen_Trading
4
NTEC Trying ....AGAINNTEC trying to break and hold above this 786 fib level ....AGAIN. It was a previous area of support leading up to the last sell-off but since breaking below it has remained a sticky level of resistance. "Aside from the cannabis directive, the company has also built a stronger pipeline for things like cancer. In fact, late last month, a patent abstract from Decoy surfaced. It showed that this was for Decoy’s “Compositions and methods for treatment of cancer using bacteria’ and that the patent was granted. With the latest proposed merger seemingly coming to fruition, this additional piece could give the company more exposure to the mounting cancer trend in the market recently. Shares have catapulted to highs of $17.80 during the week." Read More about this Decoy/Intec Deal: 3 Biotech Penny Stocks To Watch On Robinhood IPO Day
N
by PennyStocks101
PAVM Wayback MachineHad to go way back to find some levels to plot against and 2017 looks like it's the mark. The interesting part is that this 236 area has been an area of traffic in the past. Considering that PAVM failed to break and hold (for now) once again might reinforce that idea. Prior to reaching those highs, the stock tested this area a few more times but failed at every pass besides 1. "The progress from Lucid is one aspect that traders are watching with PAVmed. However, an earlier development this summer may have also acted as a catalyst for the record-setting move in 2021. Once again, this involves Lucid’s EsoGuard test. It received a European CE mark certification. This now allows the test to be marketed in numerous European countries...While PAVmed isn’t developing a cancer treatment, the EsoGuard platform is the first step to potential prevention. According to the company, it is the first and only commercially available diagnostic test capable of widespread screening to prevent esophageal cancer deaths through early detection of esophageal precancer and cancer in at-risk chronic heartburn patients." Quote Source: 3 Biotech Penny Stocks To Watch On Robinhood IPO Day
NASDAQ:PAVM
by PennyStocks101
FXCM's BioTech Basket Short-Term Pullback in Daily StrengthFXCM's BIOTECH basket is in the bullish area on the daily chart on the left. The basket is made up of equal weighting of 2% each in ABBV, AMGN, GILD, CELG and VRTX. A bullish cross of EMAs and stochastic potentially align short-term traders with the daily. If signals occur, movement of stochastic to 80 level and maintenance of that level increase chance of a successful trade in terms of 4 point pattern (red 1234). Trend following indicators may be useful in this case as a potential exit tool. Stop under hourly support in conjunction with risk management techniques.
FX:BIOTECHLong
by FXCM
4
Is LABD looking to break out of this ascending triangle?As far as popular reversal patterns go, ascending triangles are no bottom of the barrel. Although I still am a new trader, I have been committed to the market for just over 1 year. With that said I have been watching LABD/LABU in proximity of market trends. When the overall market is bullish I trade LABU with success. When Market is bearish I trade LABD with success. My number #1 rule is follow the trend. That is why I am bullish on LABD. With the market making irrational highs despite COVID fears of a new variant, I have noted that LABD make this ascending triangle formation. So far it has held true. This could just be paranoid shizophrenia (I have an MD by the way), but my inner voice has been telling me to watch biotech for the market fall. My theory is that if and when the market falls LABD is going to get pumped like there is no tomorrow, similar to the VIX. But the good part is it is not as volatile as fear is. I can trade its inverse and watch the volume in both directions. So far it seems even, so i don't think any one knows what is coming next, except for maybe the FED. Unless LABU turns around I think LABD can go up to 40, if in fact there is a bubble burst on the horizon.
AMEX:LABDLong
by umaidsiddiqui786
1
The boomers didn't have enough kids trendThe london area and some countries are ordering millions of body bags. They are super bearish. At the bottom. As usual. Covid is over. There were 2 deadly waves and there won't be a third. I hope I'm not offending anyone too much. I know that to big brains going against the fear narrative - which changes everyday - makes you a conspiracy theorist that believes jewish lizards control the world. I believe reptilians control the world and this is my right. Look at this chart: Do you not think that governments are ran by reptilian brains because I think they are. They made illegal buying masks and told us they were useless. Then they forced us to wear masks and used strict police repression to enforce this rule. They locked healthy people at home, even in middle ages they didn't do that. Scientists proved it was useless AND showed that for the first time ever, entire families (locked together) died! They are always wrong about everything. They are reptilian peasants. Covid passes, just like retirement reforms, are rules made by boomers for boomers. And these rules apply to everyone except the police and military. Democracy. It's like literally everyone is ultra bullish on covid but they are all wrong. This is the top. They are going to panic with the violent 2023 flu pandemic but it's just the start of wave 1 in the new uptrend. And 2022 will be "back to normal hurrah". After 1 century of exceptional progress, S&P growth, life expectancy, the trend will reverse. Good times create weak men etc. These weak zombies will panic it's going to be funny. When a very violent bubonic ebola plague hits it's possible that the zombies get the zeal of the convert: They believed in covid fear, they will change their mind once it's over and they slowly learn restrictions were for nothing. Redpilled. And so, when the plague hits they will brush it off. I'll be in my bunker in the middle of nowhere watching natural selection take its course. Deaths will actually go up for several reasons: - Massive obesity, in particular in the young (that are getting older and fatter) - Massive old population with very little replacement And also: - Weak chinned low T drug addicts - Hypocondriacs with weakened immune systems - Being stuck at home and other small reasons Medical institutions have done a lot of campaigning to get people to avoid using antibiotics all the time. Some fear penicillin resistant bacterias pandemics and mutants. This will not happen, not on a large scale. Bacterias have been at war for BILLIONS of years. Using penicillin or other antibiotics for millions of years. Zambia is a country with a population of 15,000,000. The west stole almost all their doctors. They had 1600 and that number dropped to 400. This obviously really screws the country beyond belief but a few thousand doctors for the west is not enough. They have a few hundred per 100,000 and as the population age they will need more, perhaps as much as 500/100,000. But their doctors are retiring, so the number goes down. In France the number now is 330, stagnating, but the number of patients is going up. And that 330 number will decline. France alone might need 100 doctors by 100,000. So in total 67,000 doctors (the population is 67M). That is more than 50 times the number of doctors that were stolen from Zambia. And that's France alone. Plus the "brain drain" has been going on for decades so Africa has little left to leech. Maybe they are now letting in refugees because they hope some of them will turn into doctors? For context at least 70% of refugees are women and children. The revolution already started, but during the 2023 flu pandemic where thousands of old people are waiting in makeshift beds in tents because hospitals are full, and the government runs out of options (they might lock people at home again, out of despair again), a hard paradigm change will be necessary. There are a lot of variable. For example if the anti covid injections have side effects, pharma companies, that already have scandals way too often, will lose the public trust. And the biotech period will not happen, or be delayed, or be very secondary. We are changing of paradigm & period (50-75 years), but also of era (200-300). The period in France is 1968-2021 so 53 years. Or you could say since the 1946 NWO, 75 years. It is not an exact science. The past 50-75 years was the period of neo-liberal pleasure seaking, tech religion, etc. It's ending. That was for the period (50-75). The era (200-300) is industrial revolution/wageslavery/capitalism/socialism. We were born just in time to witness some of the greatest change in history. Worth it. All of Africa does not have enough doctors and nurses to take care of the hundred of millions of obese and old patients. Not even close. The only half valid hope is technology but it won't magically save people. Deaths will go up, like it or not. And governments can crush revolts, but they can't crush the underlying fundamentals. If Louis XVI had put an end to the tax revolt of 1789 (Like Macron put an end to the yellow vest tax revolt), monarchy would still have ended. The trend, and what to expect is clear. I believe not 1 in a thousand knows this. It is mathematically impossible the welfare state continues, government guarenteed pensions will vanish. And it is mathematically impossible that our generation (Z to X) lives better than boomers. For the first time the kids will not be better off than their parents. Not only that but even much worse off. I will add another call, gold, easy one: I hate explaining the obvious but I have the intention to throw this at the face of dum dums. Here I am so clear even a zombie should be able to understand: Months ago me said covid-19 wave was over, and me said if other wave it would be other variant. Which was the case. That call aged well. Now me say covid deaths any variant is over. I no care media say "ooga booga many case". Me say death spike covid any variant over. No more big spike. No third deadly wave. Understand? Death. Not case. Regardless vaccines. All country same.
TVC:GOLD
by MrRenev
1
ADDED to $ATOS Target 6.84 for 35.71% 🟢 $ATOS Target 6.84 for 35.71% This one was caught by support so I added… I’ll add again at support if it goes that way… And if it breaks below I’ll double at 3.24 ----- — On the far right of the chart is my Average (Grey) Current Target (Green), and Next Level to add (Red) Percentage to target is from my average. Numbers with an A are places that are a good idea to add if you can. Numbers with a D are places where you should double your position. I start every position with .5 - 1% of my account and build from there as needed and as possible. I am not your financial advisor. Watch my setups first before you jump in… My trade set ups work very well and they are for my personal reference and if you decide to trade them you do so at your own risk. I will gladly answer questions to the best of my knowledge but ultimately the risk is on you. I will update targets as needed. GL and happy trading.
NASDAQ:ATOSLong
by SPYder_QQQueen_Trading
5
NURO Fibbing Right Now Or New Highs Next?I took the NURO chart out to 2019, which was the last time it traded around these levels. After plotting these fibs, wouldn't you know, the 236 and 382 lined up almost EXACTLY with today's action. The 382 could be an important level to watch as this was a prior area of "high traffic" and a support/resistance pivot in 2019. With volume surging, 382 fib line could be a key level t pay attention to. **The big spike in trading action on July 20th stemmed from FDA news. NeuroMetrix announced that it received FDA Breakthrough Device Designation for treating fibromyalgia. Specifically, its Quell device garnered the interest of the stock market today. The device is non-invasive and is a nerve stimulator covered by 18 U.S. utility patents already. This Breakthrough Device Program aims to help patients gain quicker access to technologies like Quell that could provide more effective treatments. “We are moving forward with a regulatory filing that could position us to launch Quell for this indication in the second half of next year.” Shai N. Gozani, M.D., Ph.D., President and CEO of NeuroMetrix Later this week, the company releases its Q2 results. So if NURO stock is on your list right now, keep July 22nd in mind. The company will also host a conference call before the market opens on that day. Read More On NeuroMetrix .** Quote Source: 4 Penny Stocks To Watch As Hedge Against Dogecoin Price Drop Today
NASDAQ:NURO
by PennyStocks101
Between Two Fibs - AEMDAEMD seems to like this range between the 786 and 618 fib lines. The 618 has long-been a point of resistance on the chart. Meanwhile, the last few days have seen it test the 786 level but hold both above it AND its 50DMA. No news today but focus on biotechs thanks to CYTK earlier could be a sympathy trigger at play. Also with the Delta varient becoming "a thing," covid stocks in numerous stages of development are becoming more of a focus right now. We'll have to see if 786 fib+ 50DMA post a strong support level and if 618 will remain resistance if or when AEMD takes another swing at it.
NASDAQ:AEMD
by PennyStocks101
Not Much Fib With NRXP But Levels, Yes!Fib Retracement on NRXP doesn't show much by way of "important levels" until you get to the 786 if you use that ATH for the top of your fib set-up. BUT if you look back on the chart, there's a pretty clear level right AT the area NRXP stock is trading at after this news. Around $12.70 was a previous area where the stock tested but didn't break below. Now, since breaking below, this seems to be a level that it can't break above. However, after the news came out, NRXP has treaded water between 11.50 & $12 in a consolidation trend during the 7/19 session. Volume will be something to keep an eye on moving forward in deciding which way it will break. "Shares of NRXP were also going against the grain of the broader biotech trend at the start of the week. NRX Pharmaceuticals (NRXP Stock Report) announced that it will present data at the Disease Control and Prevention Summit this week. Wednesday (7/21) the company provides evidence that its YESAMI treatment might help prevent “cytokine storm” in patients with COVID-19. According to the company, 'In the recently-completed phase 2b/3 trial, patients treated with placebo experienced a statistically significant elevation in interleukin 6 (IL-6) cytokine levels, whereas those treated with ZYESAMI™ had a minimal increase in IL-6. Change in cytokine level was a prespecified endpoint of the study.'” Quote Source: Small-Cap Stocks To Watch After CYTK Sheds Spotlight On Biotech
NASDAQ:NRXP
by PennyStocks101
New Highs & Levels For CYTKCYTK put in a fresh high today which was rejected HARD almost immediately after. This came after the company announced positive topline results from 2 cohorts in its REDWOOD-HCM Phase 2 clinical trial of CK-3773274 (CK-274). This is the company’s investigational treatment targeting hypertrophic cardiomyopathy. “The combined data from Cohorts 1 and 2 in REDWOOD-HCM met our high expectations for this trial of CK-274 in patients with obstructive HCM, given the observed onset of response to initiation of treatment, magnitude and breadth of response, reversibility of LVEF decreases, and favorable tolerability profile,” said Fady I. Malik, M.D., Ph.D., Cytokinetics’ Executive Vice President of Research & Development. Looks like the 236 fib line - using lows from the major gap down - has been a pivot over the last year or so. CYTK tested that level on July 19th and bounced during the morning session. The big question is can it maintain this as a new support level or is it looking at another breakdown following this huge move? "Thanks to these results, Cytokinetics expressed its anticipation of what its Phase 3 trial could bring to the table. Let’s put this into perspective. CYTK wasn’t any of the penny stocks that broke out last year. However, its valuation was a fraction of what it is today. Last October, CYTK stock was trading around $15 a share; more than 50% less than its value on July 19th. With that, attention is certainly on smaller biotech stocks right now." Quote Source: Small-Cap Stocks To Watch After CYTK Sheds Spotlight On Biotech
NASDAQ:CYTK
by PennyStocks101
Biotech - CSLModel has given entry signals for CSL Limited: - CSL Limited is a global specialty biotechnology company that researches, develops, manufactures, and markets products to treat and prevent serious human medical conditions. - We are very excited about opportunities in the biotech sector, as we believe the fight against COVID is going to move to the next phase in the nearest future. - Technically in a Wyckoff accumulation structure with a spring, possibly testing the channel top. GLHF, DPT Disclaimer: We absolutely do not provide financial advice in any shape or form. We do not recommend investing based on our opinions and strongly cautions that securities trading and investment involves high risk and that you can lose a lot of money. Loss of principal is possible. We do not recommend risking money you cannot afford to lose. We do not guarantee future performance nor accuracy in historical analyses. We are not registered investment advisors. Our ideas, opinions and statements are not a substitute for professional investment advice. We provide ideas containing impersonal market observations and our opinions. Our speculations may be used in preparation to form your own ideas.
ASX:CSLLong
by UnknownUnicorn1043646
Bullish Reversal after Options Expiration Today for GALTGALT reported positive results for cancer immunotherapy one week ago. This was followed by algorithm trading taking the stock price lower. There is high open interest on $3, $4, and $5 calls expiring today. The price should reverse and move higher with the expiration of these calls, since the options traders accomplished what they were after to keep below the strike price and will now cover their short positions. TipRanks data on 488,633 investor portfolios show that 8.4% more portfolios hold GALT in the last 7 days, so there is growth in the investor base. The temporary dip is from the options traders. (See my previous Idea for summary notes on the due diligence setup.)
NASDAQ:GALTLong
by LGALS3
OCGN back to basicsOCGN kind of treading water for now. I think what we need to see are some rock-solid results from COVAXIN, which this rolling submission could be helpful in identifying. The Phase 3 results were interesting. With more warnings coming out about the current SOC EAU vaccines, another option might not be "too late" at this point. But a lot will clearly come down to the results. For now, speculation is probably playing a bigger role as we don't know much more beyond what Ocugen announced this week. Regardless, looking at chart levels, a quick Fib retracement shows a few "pain points" on the chart, namely the 618 fib that has been a frequent resistance level over the last few months. "On July 2nd, Ocugen reported new evidence from Bharat Biotech. The company shared positive results of its Phase 3 study of COVAXIN™; a whole virion inactivated COVID-19 vaccine candidate. According to the company, it demonstrated a vaccine efficacy in mild, moderate, and severe COVID-19 disease of 77.8% with efficacy against severe COVID-19 disease alone of 93.4%. “With the Delta variant becoming a dominant strain of COVID-19 in the United States, we believe that the Phase 3 efficacy results reported by Bharat Biotech demonstrate that COVAXIN™ has the potential to become an important option to expand protection against this emerging variant. Combining these data with the only Delta-variant results from a controlled Phase 3 clinical trial, evidence continues to support a favorable benefit-risk profile for COVAXIN™.” - Dr. Bruce Forrest, Acting Chief Medical Officer and a member of the vaccine scientific advisory board of Ocugen. " Quote Source: 7 Penny Stocks For Your Watch List This Week If You Like Biotech In July
NASDAQ:OCGN
by PennyStocks101